New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis – BioSpace
By daniellenierenberg
Sept. 11, 2020 05:00 UTC
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data that show Ocrevus (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analysis from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
For a wide range of people with MS who experienced a suboptimal response to prior treatment, we continue to see evidence that Ocrevus provides significant benefit in slowing disease progression, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. New real-world Ocrevus data show high persistence and adherence to the only B-cell therapy with a twice-yearly dosing schedule, which we know can be very important to both people with MS and their physicians.
Phase IIIb open-label CASTING study
Approximately 75% of RRMS patients (492/658) had no evidence of disease activity (NEDA; brain lesions, relapses and worsening of disability) two years after switching to twice-yearly Ocrevus treatment (with prespecified MRI re-baselining at 8 weeks) in the primary analysis of the CASTING study. Patients enrolled in the study had prior suboptimal response to at least six months of treatment with up to two DMTs. The analysis also showed the proportion of patients achieving NEDA remained consistently high across all measured patient subgroups, including baseline MRI activity, relapse activity, disability level, age and the number of prior DMTs. Further, 78% of patients treated with only one prior DMT compared with 70% of patients treated with two prior DMTs achieved NEDA.
Additionally, patients treated with Ocrevus experienced an improvement in the majority of symptoms measured by SymptoMScreen after two years. SymptoMScreen is a patient-reported outcome tool to assess symptom severity across twelve domains. The most pronounced significant improvements (p<0.001) were seen in sensory symptoms, fatigue and vision, which are important for daily living.
CONFIDENCE real-world safety study
A 97% treatment persistence for Ocrevus patients at 18 months, and strong adherence to infusions every six months, was seen in an interim analysis of more than 1,600 patients in the ongoing German CONFIDENCE study. Separate data from a U.S. commercial claims database that support high persistence and sustained adherence to Ocrevus treatment will also be presented.
Ocrevus longer-term safety data
New safety data as of January 2020 will be presented, representing 5,680 patients with RMS and PPMS and 18,218 patient-years of exposure to Ocrevus, across all Ocrevus clinical trials. These findings further demonstrate the consistently favorable benefit:risk profile of Ocrevus over seven years.
With rapidly growing real-world experience and more than 170,000 people treated globally, Ocrevus has twice-yearly (six-monthly) dosing and is the first and only therapy approved for RMS (including relapsing-remitting MS [RRMS] and active, or relapsing, secondary progressive MS [SPMS], in addition to clinically isolated syndrome [CIS] in the U.S.) and primary progressive MS (PPMS). Ocrevus is approved in 92 countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia, Switzerland and the European Union.
About multiple sclerosis
Multiple sclerosis (MS) is a chronic disease that affects nearly one million people in the United States, for which there is currently no cure. MS occurs when the immune system abnormally attacks the insulation and support around nerve cells (myelin sheath) in the brain, spinal cord and optic nerves, causing inflammation and consequent damage. This damage can cause a wide range of symptoms, including muscle weakness, fatigue and difficulty seeing, and may eventually lead to disability. Most people with MS experience their first symptom between 20 and 40 years of age, making the disease the leading cause of non-traumatic disability in younger adults.
Relapsing-remitting MS (RRMS) is the most common form of the disease and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. Approximately 85 percent of people with MS are initially diagnosed with RRMS. The majority of people who are diagnosed with RRMS will eventually transition to secondary progressive MS (SPMS), in which they experience steadily worsening disability over time. Relapsing forms of MS (RMS) include people with RRMS and people with SPMS who continue to experience relapses. Primary progressive MS (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15 percent of people with MS are diagnosed with the primary progressive form of the disease. Until the FDA approval of Ocrevus, there had been no FDA approved treatments for PPMS.
People with all forms of MS experience disease activity inflammation in the nervous system and permanent loss of nerve cells in the brain even when their clinical symptoms arent apparent or dont appear to be getting worse. An important goal of treating MS is to reduce disease activity as soon as possible to slow how quickly a persons disability progresses. Despite available disease-modifying treatments (DMTs), some people with RMS continue to experience disease activity and disability progression.
About Ocrevus (ocrelizumab)
Ocrevus is the first and only therapy approved for both RMS (including clinically isolated syndrome, RRMS and active, or relapsing, SPMS) and PPMS, with dosing every six months. Ocrevus is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, Ocrevus binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved.
Ocrevus is administered by intravenous infusion every six months. The initial dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions.
Important Safety Information
What is Ocrevus?
Ocrevus is a prescription medicine used to treat:
It is not known if Ocrevus is safe or effective in children.
Who should not receive Ocrevus?
Do not receive Ocrevus if you have an active hepatitis B virus (HBV) infection.
Do not receive Ocrevus if you have had a life threatening allergic reaction to Ocrevus. Tell your healthcare provider if you have had an allergic reaction to Ocrevus or any of its ingredients in the past.
What is the most important information I should know about Ocrevus?
Ocrevus can cause serious side effects, including:
These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion.
If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
Before receiving Ocrevus, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of Ocrevus?
Ocrevus may cause serious side effects, including:
Most common side effects include infusion reactions and infections.
These are not all the possible side effects of Ocrevus.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
For more information, go to http://www.Ocrevus.com or call 1-844-627-3887.
For additional safety information, please see the full Prescribing Information and Medication Guide.
About Genentech in neuroscience
Neuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.
Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, stroke, Alzheimers disease, Huntingtons disease, Parkinsons disease, Duchenne muscular dystrophy and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910006081/en/
- Eye stem cell transplant to treat blindness bolsters retinal function in monkeys - FierceBiotech - January 14th, 2021
- Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire - January 14th, 2021
- Reversing The Aging Clock With Epigenetic Reprogramming - Bio-IT World - January 14th, 2021
- Bath And Body Routines That Make You Look And Feel Good From Day To Night - Forbes - January 12th, 2021
- Worldwide Organ and Tissue Transplantation and Alternatives Industry to 2024 - Featuring Mylan, Novartis & Pfizer Among Others -... - January 12th, 2021
- BENEV Announces Investigative Report on Combination Treatment with Human Adipose Tissue Stem Cell- derived Exosomes and Fractional CO2 Laser for Acne... - January 9th, 2021
- Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years - Endpoints News - January 9th, 2021
- Spinogenix Wins Grant to Advance Testing of Potential Oral Therapy - ALS News Today - January 9th, 2021
- Ulta Beautys Love Your Skin Event Is Here | January 2021 - Allure - January 9th, 2021
- Exosome Therapeutic Market Overview By Size, Share, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry Structure - KSU |... - January 9th, 2021
- Global Organ and Tissue Transplantation and Alternatives Market to 2024 - Impact Analysis of COVID-19 - Yahoo Finance - January 9th, 2021
- A celebrity dermat's tips for new moms on how to deal with postpartum hair and skin issues - VOGUE India - January 9th, 2021
- FOREO UFO 2 Review: Is It Worth The Hype? - GLAMOUR UK - January 9th, 2021
- The Amniotic Fluid Stem Cell Therapy Market to be synonymous to vertical growth between 2018 and 2026 - LionLowdown - January 5th, 2021
- 2021: What are the best self-care products to buy in the new year? - The Jerusalem Post - January 3rd, 2021
- The Complete Guide to Laser Treatments for Hair and Skin | The Science of Beauty Podcast | Allure - Allure - December 30th, 2020
- The big scientific breakthroughs of 2020 - The Week - December 30th, 2020
- Nociceptive neurons shown to boost hematopoiesis | 2020-12-28 - BioWorld Online - December 28th, 2020
- Getting to the root of why hair goes gray - messenger-inquirer - December 26th, 2020
- What causes chafing rash? Remedies, treatment, and prevention - Medical News Today - December 24th, 2020
- Rash on black skin: Pictures, symptoms, and treatments - Medical News Today - December 24th, 2020
- Everything You've Ever Wanted to Know About Body Hair - Allure - December 24th, 2020
- 2020 in Neuroscience, Longevity, and AIand What's to Come - Singularity Hub - December 22nd, 2020
- Hair loss, body odor, irregular periods: Covid-19 isolation does weird things to our bodies - Vox.com - December 22nd, 2020
- Scientists have restored youth to aging eyes in mice - Massive Science - December 21st, 2020
- The Adrenomyeloneuropathy Treatment Market to grow on an emphatic note from 2019 to 2029 - PharmiWeb.com - December 21st, 2020
- At 14.6% CAGR, Cell Banking Outsourcing Market 2020 Industry Analysis of Current Trends and Opportun - PharmiWeb.com - December 21st, 2020
- The Definitive Guide to All Things Vegan By Drunk Elephant - LIVEKINDLY - December 21st, 2020
- The facts about the danger of melanoma - The Hudson Reporter - December 17th, 2020
- A Tried And Tested Guide On How To Win The War Against Maskne - Forbes - December 13th, 2020
- COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters) - DocWire News - December 10th, 2020
- Avenoir Cosmetics Launches Cell Repair Serum - Clinical Strength to Enhance Skin Tone & Minimize Appearance of Sunspots, Blemishes, Discoloration,... - December 10th, 2020
- CBD: the beauty ingredient trend that can't be stopped - CosmeticsDesign.com USA - December 10th, 2020
- The Technology Behind Bone Marrow Cellular Processing: The PXP System - marketscreener.com - December 9th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - BioSpace - December 9th, 2020
- How to Minimize Inflammation and Prevent Your Skin from Inflammaging - Coveteur - December 5th, 2020
- Reversing vision loss by turning back the aging clock - FierceBiotech - December 5th, 2020
- Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders - PRNewswire - December 5th, 2020
- The Amniotic Fluid Stem Cell Therapy Market to Cascade the Success Trove - The Haitian-Caribbean News Network - December 2nd, 2020
- Global Anti-Ageing Drugs Industry Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 - The Courier - December 2nd, 2020
- Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed - December 2nd, 2020
- The end-use Industries to Help the Medical Skin Care Products Market stand in a good stead between 2017 and 2025 - Cheshire Media - November 30th, 2020
- What exactly is the revolutionary Smart Beauty Technology, and how Kira Sorokina, the Founder of NanoAsia leads it - Press Release - Digital Journal - November 30th, 2020
- Everything to Know About Inflamm-aging - NewBeauty Magazine - November 25th, 2020
- 'This is why I'm here': A Detroit Lions VP tries to save her daughter from rare disease - ESPN - November 25th, 2020
- Israeli Scientists Discover Oxygen Beauty Treatment That Can Make You Look 25 Years Younger - All You Need to - India.com - November 25th, 2020
- Mysteries of COVID smell loss finally yield some answers - Livescience.com - November 20th, 2020
- Four life-changing wellness retreats from around the world - Euronews - November 20th, 2020
- Avrobio tracks improvements in first patient treated with Gaucher gene therapy - FierceBiotech - November 20th, 2020
- As California Passes Prop 14, What Is Stem Cell Research and Why Is It Controversial? - Newsweek - November 18th, 2020
- Mibelle Biochemistry's Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market Lauded by Frost & Sullivan - PR Newswire... - November 18th, 2020
- Mibelle Biochemistry announces: Mibelle Biochemistrys Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market by Frost and... - November 18th, 2020
- Real life 'Barbie and Ken' achieve doll-like looks with futuristic stem-cell injections - Daily Star - November 18th, 2020
- The Induced Pluripotent Stem Cells Market To Witness Fierce Competition Amongst The Key Players - KYT24 - November 18th, 2020
- La Prairies New Collection Is Inspired by a Platinum Meteor Shower that Lasted 200 Million Years - Surface Magazine - November 18th, 2020
- The New Generation Of Beauty - Forbes - November 18th, 2020
- The Medical Skin Care Products Market to personify growth in the next decade - PRnews Leader - November 12th, 2020
- 7 misleading 'facts' about skin that just aren't true - IOL - November 12th, 2020
- Red algae and sheep placenta: 9 bizarre but effective skincare ingredients that actually work - VOGUE India - November 12th, 2020
- Alstom SA: Availability of the half-year financial report as at 30 September 2020 - Yahoo Finance UK - November 12th, 2020
- The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology - The Think Curiouser - November 8th, 2020
- Cell Expansion Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights -... - November 8th, 2020
- The Medical Skin Care Products Market to witness non-linear transition from 2017 to 2025 - PRnews Leader - November 5th, 2020
- A Review of Stem CellBased Therapies for Parkinson Disease - AJMC.com Managed Markets Network - November 5th, 2020
- Research providing better understand of graying hair | Health - Galveston County Daily News - November 5th, 2020
- Global Anti-Ageing Drugs Market (2020) to Witness Huge Growth by 2026 | La Roche-Posay, Revision Optics, Calico, Nu Skin, L'ORAL, Unity Biotechnology,... - November 5th, 2020
- Here's how to treat those brown spots on your face, chest and hands. - Mamamia - November 3rd, 2020
- Gommage (Gentle Exfoliation) Benefits, Precautions, and How to Do It - Healthline - November 3rd, 2020
- Impact Of Covid 19 On Anti-Ageing Drugs 2020 Industry Challenges Business Overview And Forecast Research Study 2026 - Zenit News - November 1st, 2020
- What is liposuction? How the procedure works and how painful it is - Business Insider India - October 31st, 2020
- The Medical Skin Care Products market to grow on a prudent note from 2017 to 2025 - TechnoWeekly - October 30th, 2020
- You Can Influence The Way Your Skin AgesHere's How - Tatler Singapore - October 30th, 2020
- Global Growth Trends and Competitive Analysis of Skin Care Cosmetic Research Report from 2020-2026 - KYT24 - October 30th, 2020
- Stem Cell Therapy Market to Register Unwavering Growth During 2025 - The Think Curiouser - October 30th, 2020
- The Medical Skin Care Products market to witness non-linear transition from 2017 to 2025 - Eurowire - October 29th, 2020
- APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an Off-the-Shelf Allogeneic Stem Cell Product for the Treatment of... - October 29th, 2020
- Rejuvenating Austin spa puts holistic health and wellness on the table - CultureMap Austin - October 29th, 2020
- "Peptide King" Pietro Simone Is Bringing His Treatments and Products to the US - NewBeauty Magazine - October 29th, 2020
- Next-gen skincare, silk without spiders and pollution for lunch: Meet the biotech startups pitching at IndieBios Demo Day - TechCrunch - October 29th, 2020
- Impact Of Covid-19 on Cosmetic Skin Care Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - PRnews Leader - October 29th, 2020
